Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$38.15
-6.4%
$30.96
$16.50
$43.58
$3.32BN/A48,616 shs5,654 shs
Merus N.V. stock logo
MRUS
Merus
$54.29
-1.5%
$50.55
$33.19
$62.98
$3.75B1738,324 shs189,617 shs
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$50.54
+0.5%
$41.59
$26.70
$91.83
$1.02B2.6368,473 shs219,153 shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$29.30
-5.6%
$36.67
$29.04
$60.37
$2.75B0.26912,142 shs3.54 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-2.70%-4.92%+36.25%+117.86%+4,073,999,900.00%
Merus N.V. stock logo
MRUS
Merus
+1.10%+2.36%-2.37%+31.31%-1.27%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
+0.20%+6.40%+9.71%+69.13%+4.97%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-25.12%-20.82%-17.28%-9.11%-26.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
2.2055 of 5 stars
3.61.00.00.02.52.50.0
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.8298 of 5 stars
4.42.00.00.02.01.70.0
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
4.0267 of 5 stars
3.51.00.03.82.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.00
BuyN/AN/A
Merus N.V. stock logo
MRUS
Merus
3.14
Buy$84.6455.91% Upside
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.78
Moderate Buy$94.1186.20% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.93
Moderate Buy$85.36191.35% Upside

Current Analyst Ratings Breakdown

Latest PRAX, RARE, AAPG, and MRUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$88.00 ➝ $65.00
7/8/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$97.00 ➝ $115.00
6/20/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$64.00
6/12/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/2/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform$97.00
5/28/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$65.00
5/23/2025
Merus N.V. stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/19/2025
Merus N.V. stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/9/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.00
5/8/2025
Merus N.V. stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
5/7/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$134.35M24.74N/AN/A$0.48 per share79.48
Merus N.V. stock logo
MRUS
Merus
$36.13M103.99N/AN/A$9.46 per share5.74
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$8.55M120.42N/AN/A$23.90 per share2.11
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$560.23M4.94N/AN/A$2.76 per share10.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-$55.54MN/A0.00N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$182.82M-$10.72N/AN/AN/A-2,137.48%-50.42%-46.74%8/12/2025 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)

Latest PRAX, RARE, AAPG, and MRUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.27N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/6/2025Q1 2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million
5/2/2025Q1 2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.24
1.26
1.26
Merus N.V. stock logo
MRUS
Merus
N/A
5.86
5.86
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/A
8.44
8.44
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
2.40
2.24
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
60087.12 millionN/AN/A
Merus N.V. stock logo
MRUS
Merus
3769.21 million66.05 millionOptionable
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
11020.37 million19.82 millionOptionable
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,29494.54 million89.34 millionOptionable

Recent News About These Companies

Ultragenyx (RARE) Stock Sinks 25%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$38.15 -2.59 (-6.36%)
As of 03:08 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Merus stock logo

Merus NASDAQ:MRUS

$54.28 -0.83 (-1.50%)
As of 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Praxis Precision Medicines stock logo

Praxis Precision Medicines NASDAQ:PRAX

$50.54 +0.24 (+0.49%)
As of 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$29.30 -1.74 (-5.62%)
As of 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.